// App-Quantinova.ai

: Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF

Researchers

Presenter

  • J L Halperin

Principal Investigators

  • C Teutsch

  • M V Huisman

  • H.-C Diener

  • K J Rothman

  • C S Ma

  • S J Dubner

  • K Zint

  • L Riou Franca

  • M Paquette

Medical Centers

  • The Mount Sinai School of Medicine, New York, United States

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Leiden University Medical Centre, Leiden, Netherlands

  • University Hospital of Essen, Essen, Germany

  • RTI Health Solutions, Research Triangle Park, North Carolina, United States

  • Beijing Children's Hospital, Beijing, China (People's Republic)

  • Clinica y Maternidad Suizo Argentina, Buenso Aires, Argentina

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

  • Boehringer Ingelheim Corporation, Ridgefield, CT, United States of America

  • Boehringer Ingelheim Corporation, Burlington, Canada

Locations

  • Germany

  • Netherlands

  • Argentina

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pradax

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved